Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, non-randomized, open-label, multicenter, single-arm exploratory
pharmacogenomic study of single agent eribulin as neoadjuvant therapy in patients with
operable Stage III HER2 non-overexpressing breast cancer.